Sylvie Boutin

2.1k total citations · 1 hit paper
18 papers, 1.6k citations indexed

About

Sylvie Boutin is a scholar working on Genetics, Molecular Biology and Oncology. According to data from OpenAlex, Sylvie Boutin has authored 18 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 10 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Sylvie Boutin's work include Virus-based gene therapy research (13 papers), RNA Interference and Gene Delivery (6 papers) and CAR-T cell therapy research (5 papers). Sylvie Boutin is often cited by papers focused on Virus-based gene therapy research (13 papers), RNA Interference and Gene Delivery (6 papers) and CAR-T cell therapy research (5 papers). Sylvie Boutin collaborates with scholars based in France, United States and Canada. Sylvie Boutin's co-authors include Carole Masurier, P. Véron, Christian Leborgne, Olivier Benvéniste, Marie Montus, Eric J. Kremer, Olivier Danos, Miguel Chillón, Claire Soudais and Samir Saheb and has published in prestigious journals such as The Journal of Immunology, PLoS ONE and Journal of Virology.

In The Last Decade

Sylvie Boutin

17 papers receiving 1.6k citations

Hit Papers

Prevalence of Serum IgG a... 2010 2026 2015 2020 2010 250 500 750

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sylvie Boutin France 13 1.2k 1.1k 453 256 226 18 1.6k
Kenneth H. Warrington United States 17 1.5k 1.2× 1.4k 1.3× 277 0.6× 229 0.9× 239 1.1× 20 1.9k
Julio Sanmiguel United States 21 1.1k 0.9× 1.1k 1.1× 263 0.6× 294 1.1× 264 1.2× 28 1.7k
Joshua C. Grieger United States 17 1.7k 1.4× 1.9k 1.8× 383 0.8× 290 1.1× 264 1.2× 21 2.6k
Leszek Lisowski Australia 25 1.2k 1.0× 1.7k 1.6× 252 0.6× 206 0.8× 180 0.8× 80 2.3k
Jenny McIntosh United Kingdom 22 1.1k 0.9× 1.2k 1.1× 441 1.0× 90 0.4× 157 0.7× 44 1.8k
Gregory M. Podsakoff United States 14 1.8k 1.5× 1.7k 1.6× 633 1.4× 280 1.1× 247 1.1× 19 2.4k
Keyun Qing United States 25 1.8k 1.4× 1.6k 1.5× 336 0.7× 273 1.1× 338 1.5× 33 2.1k
Scott McPhee United States 16 1.4k 1.1× 1.6k 1.5× 326 0.7× 332 1.3× 122 0.5× 27 2.2k
Margaret Humphries United States 10 863 0.7× 893 0.8× 286 0.6× 155 0.6× 156 0.7× 15 1.3k

Countries citing papers authored by Sylvie Boutin

Since Specialization
Citations

This map shows the geographic impact of Sylvie Boutin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvie Boutin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvie Boutin more than expected).

Fields of papers citing papers by Sylvie Boutin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sylvie Boutin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvie Boutin. The network helps show where Sylvie Boutin may publish in the future.

Co-authorship network of co-authors of Sylvie Boutin

This figure shows the co-authorship network connecting the top 25 collaborators of Sylvie Boutin. A scholar is included among the top collaborators of Sylvie Boutin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sylvie Boutin. Sylvie Boutin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
McFarlane, Philip A., et al.. (2023). Eight Years of Canadian Real-World Assessment of Tolvaptan in ADPKD: C-MAJOR Study and Safety Monitoring and Distribution Program. Journal of the American Society of Nephrology. 34(11S). 209–209.
3.
Chen, Wei, et al.. (2022). Real-world evaluation of patiromer utilization and its effects on serum potassium in veterans with end stage kidney disease. Medicine. 101(50). e32367–e32367. 1 indexed citations
4.
Véron, P., Christian Leborgne, Jack‐Yves Deschamps, et al.. (2020). Capsid-specific removal of circulating antibodies to adeno-associated virus vectors. Scientific Reports. 10(1). 864–864. 80 indexed citations
5.
Gross, David‐Alexandre, Christian Leborgne, Pascal Chappert, et al.. (2019). Induction of tumor-specific CTL responses using the C-terminal fragment of Viral protein R as cell penetrating peptide. Scientific Reports. 9(1). 3937–3937. 12 indexed citations
6.
Leborgne, Christian, Sylvie Boutin, Fanny Collaud, et al.. (2018). Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients. Cellular Immunology. 342. 103780–103780. 41 indexed citations
7.
Véron, P., et al.. (2012). Humoral and Cellular Capsid-Specific Immune Responses to Adeno-Associated Virus Type 1 in Randomized Healthy Donors. The Journal of Immunology. 188(12). 6418–6424. 70 indexed citations
8.
Saheb, Samir, Sylvie Boutin, Christian Leborgne, et al.. (2011). A 10 Patient Case Report on the Impact of Plasmapheresis Upon Neutralizing Factors Against Adeno-associated Virus (AAV) Types 1, 2, 6, and 8. Molecular Therapy. 19(11). 2084–2091. 163 indexed citations
9.
Moulay, Gilles, Sylvie Boutin, Carole Masurier, Daniel Scherman, & Antoine Kichler. (2010). Polymers for Improving the In Vivo Transduction Efficiency of AAV2 Vectors. PLoS ONE. 5(12). e15576–e15576. 13 indexed citations
10.
Boutin, Sylvie, P. Véron, Christian Leborgne, et al.. (2010). Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors. Human Gene Therapy. 21(6). 704–712. 753 indexed citations breakdown →
11.
Véron, P., Sylvie Boutin, Samia Martin, et al.. (2009). Highly efficient transduction of human plasmacytoid dendritic cells without phenotypic and functional maturation. Journal of Translational Medicine. 7(1). 10–10. 18 indexed citations
12.
Masurier, Carole, Sylvie Boutin, P. Véron, et al.. (2007). Enhanced Lentiviral Transduction of Monocyte-Derived Dendritic Cells in The Presence of Conditioned Medium from Dying Monocytes. Human Gene Therapy. 18(2). 161–170. 2 indexed citations
13.
Véron, P., Sylvie Boutin, Jacky Bernard, et al.. (2006). Efficient transduction of monocyte‐ and CD34+‐ derived Langerhans cells with lentiviral vectors in the absence of phenotypic and functional maturation. The Journal of Gene Medicine. 8(8). 951–961. 12 indexed citations
14.
Soudais, Claire, Sylvie Boutin, & Eric J. Kremer. (2001). Characterization of cis-Acting Sequences Involved in Canine Adenovirus Packaging. Molecular Therapy. 3(4). 631–640. 43 indexed citations
15.
Kremer, Eric J., Sylvie Boutin, Miguel Chillón, & Olivier Danos. (2000). Canine Adenovirus Vectors: an Alternative for Adenovirus-Mediated Gene Transfer. Journal of Virology. 74(1). 505–512. 203 indexed citations
16.
Soudais, Claire, Sylvie Boutin, Saw See Hong, et al.. (2000). Canine Adenovirus Type 2 Attachment and Internalization: Coxsackievirus-Adenovirus Receptor, Alternative Receptors, and an RGD-Independent Pathway. Journal of Virology. 74(22). 10639–10649. 99 indexed citations
17.
Bonnet, Mathilde, Sylvie Boutin, Timothy T. C. Yip, et al.. (1998). Amino-acid change in the Epstein-Barr-virus zebra protein in undifferentiated nasopharyngeal carcinomas from Europe and North Africa. International Journal of Cancer. 75(4). 497–503. 29 indexed citations
18.
Klonjkowski, Bernard, Pascale Gilardi‐Hebenstreit, Juliette Hadchouel, et al.. (1997). A Recombinant E1-Deleted Canine Adenoviral Vector Capable of Transduction and Expression of a Transgene in Human-Derived Cells and In Vivo. Human Gene Therapy. 8(17). 2103–2115. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026